Loading... Please wait...
Sort by:
  • Succeeding with value based contracts
    Learn More Succeeding with value based contracts
    Get up-to-speed on value-based contracting before your competitors take the lead Hailed by some as the answer to the drug cost crisis, value-based contracting (VBC) is currently dominating the agenda in pharma...
  • Trends in Biomarkers and CDx
    Learn More Trends in Biomarkers and CDx
    Technical advances are ushering in a new era for companion diagnostics. What does Pharma need know? The introduction of liquid biopsies and advances in next generation sequencing are just the latest developments driving...
  • Charting MSL Activity & Performance 2018
    Learn More Charting MSL Activity & Performance 2018
    Benchmark your MSL practice and performance against the industry's best! The critical Medical Science Liaison (MSL) function is being stretched as the need to meet the demands of KOLs, HCPs, patients and payers grows...
  • Orphan Drug Commercial Models: Strategies for Success
    Learn More Orphan Drug Commercial Models: Strategies for Success
    Ensuring payer support, delivering stakeholder benefit and generating commercial returns: Pharma's growing orphan drug challenge Rising competition and closer scrutiny by hard-pressed payers are just two of the trends...
  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
    Learn More HTA in Europe: Key Success Factors for Positive HTA Recommendations
    Is there a magic formula for achieving HTA approvals in Europe? Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on...
  • The Impact of Nanomedicine in the Pharma Industry
    Learn More The Impact of Nanomedicine in the Pharma Industry
    Can nanomedicines really offer pharma a compelling alternative approach to precision medicines? Delivering accurate diagnosis for clinicians, safer medicines for patients and lower costs through reduced waste and costly...
  • Dark Analytics: Shining a Torch for Pharma
    Learn More Dark Analytics: Shining a Torch for Pharma
    Dark analytics can unlock a wealth of new clinical and commercial insights—but how can you make it work for you? Dark data and dark analytics have the potential to generate huge business insights, but much of this...
  • Paying for Digital Health: Payer Insights
    Learn More Paying for Digital Health: Payer Insights
    Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...
  • New Commercial Models: Benchmarking Pharma Companies [2018]
    Learn More New Commercial Models: Benchmarking Pharma Companies [2018]
    How well has your business transitioned from a volume-driven to a value-driven model? Pharma has made the shift from volume to value, but just how successful are these new commercial models proving to be? Customer first...
  • Medical Affairs in Emerging Markets
    Learn More Medical Affairs in Emerging Markets
    How can medical affairs capability be enhanced to unlock the Brazilian, Russian, Indian and Chinese pharma markets? The pharma markets of Brazil, Russia, India and China (BRIC) are becoming increasingly complex with...
  • Biosimilars: US Payer Perspectives (2018)
    Learn More Biosimilars: US Payer Perspectives (2018)
    US payers eye European biologics market with envy Biosimilars may be a roaring success in Europe but the picture in the US couldn't be more different. Once hailed as a solution to stem the tide of soaring drug spending,...
  • Benchmarking Pharma’s MSL Capabilities
    Learn More Benchmarking Pharma’s MSL Capabilities
    Are you convinced your MSL teams are keeping up with evolving market practice? The best medical science liaison (MSL) teams have made significant changes to adapt to a whole new world. The pharma companies getting the...
  • Benchmarking Key Account Management Capabilities
    Learn More Benchmarking Key Account Management Capabilities
    Are your KAM teams firing on all cylinders? If, not, why not? What makes a great KAM (Key Account Manager) and KAM team and what are the personal attributes and operational environment that will deliver optimum...
  • KAM Metrics: Driving efficiency and measuring success
    Learn More KAM Metrics: Driving efficiency and measuring success
    Sales numbers are no longer the gold standard for measuring commercial success. What is? The maturing key account management (KAM) model has transformed the way customer-facing teams operate: the challenge now is to use...
  • MSL Teams: Field Force size and structure
    Learn More MSL Teams: Field Force size and structure
    Medical Science Liaison (MSL) personnel play an ever crucial and widening role in communicating the value and science of increasingly complex therapies to opinion leaders and stakeholder groups. The challenge for senior...
  • Pricing and Reimbursement in Neurology
    Learn More Pricing and Reimbursement in Neurology
    When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved